PTFE Covered Stents Versus Naked Stents in the TIPS (Transjugular Intra-hepatic Porto-systemic Shunt)

Sponsor
University Hospital, Tours (Other)
Overall Status
Completed
CT.gov ID
NCT00593528
Collaborator
(none)
138
12
2
40.9
11.5
0.3

Study Details

Study Description

Brief Summary

Transjugular intrahepatic portosystemic shunts (TIPS) have been increasingly used for the treatment of complications of portal hypertension in patients with cirrhosis.

The initial experiment of the TIPS was reported during the 1990s with stents of various brands, manufacture and sizes, but all "non covered", thus owing the pseudointimal hyperplasia growing inside the stent, which progressively decreases the diameter of the shunt and thus its efficacy. Since the beginning of the 2000s, appeared stents known as "covered" by polytetrafluoroethylene (PTFE) designed to reduce the obstruction rate and thus the frequency shunt revisions. However, these stents are, on average, 2.5 times more expensive than the non covered stents and the cost-effectiveness ratio of the TIPS according to the type of stents used has not been assessed.

The aim of this multicentric and randomized study is to assess the cost-effectiveness ratio of these 2 principles of TIPS, the one using stents covered by PTFE, relatively expensive but seldom becoming obstructed, and the other using non covered stents, less expensive than PTFE but requiring regular gestures of redilatation.

Population concerned: Patients with a cirrhotic portal hypertension responsible for:
  • recurrent variceal bleeding

  • refractory ascite (or hydrothorax)

Condition or Disease Intervention/Treatment Phase
  • Device: Naked Stents: Wallstent® (Boston Scientific), Luminexx® (Bard), Zilver® (Cook), Palmaz Genesis® and Smart Control® (Cordis)
  • Device: PTFE Covered Stents: Fluency® (Bard), Advanta V12® (Atrium) and Viatorr® (Gore)
  • Procedure: Transjugular intrahepatic portosystemic shunt (TIPS)
N/A

Study Design

Study Type:
Interventional
Actual Enrollment :
138 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Randomized Study With Medico-economic Evaluation Comparing the Use of PTFE Covered Stents vs Naked Stent in the TIPS (Transjugular Intra-hepatic Porto-systemic Shunt)
Study Start Date :
Feb 1, 2008
Actual Primary Completion Date :
Jul 1, 2011
Actual Study Completion Date :
Jul 1, 2011

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: A

Naked Stents

Device: Naked Stents: Wallstent® (Boston Scientific), Luminexx® (Bard), Zilver® (Cook), Palmaz Genesis® and Smart Control® (Cordis)
Vascular Stents

Procedure: Transjugular intrahepatic portosystemic shunt (TIPS)
Transjugular intrahepatic portosystemic shunt (TIPS)

Experimental: B

PTFE Covered Stents

Device: PTFE Covered Stents: Fluency® (Bard), Advanta V12® (Atrium) and Viatorr® (Gore)
Vascular Stents

Procedure: Transjugular intrahepatic portosystemic shunt (TIPS)
Transjugular intrahepatic portosystemic shunt (TIPS)

Outcome Measures

Primary Outcome Measures

  1. TIPS permeability rate [one year]

  2. Cost of the TIPS and patient care according to the type of stent used brought back to an indicator of effectiveness [one year]

Secondary Outcome Measures

  1. Tolerance criteria : frequency of early complications like early thrombosis - probability of hepatic encephalopathy occurrence and gravity [one year]

  2. Quality of life [one year]

  3. Effectiveness criteria : survival rate - recurrence rate of the symptoms having justified the TIPS - various types of dysfunction [one year]

  4. Doppler : performance evaluation of Doppler for the diagnosis of dysfunction [one year]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 75 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Presence of a cirrhosis as documented by previous liverbiopsy or typical clinical signs

  • Indication validated of the TIPS (Bavéno IV), except not-controlled acute hemorrhagic :

  • Recurrent variceal bleeding after failure of the usual pharmacological and endoscopic methods

  • Refractory or recurrent ascites or difficult to treat

  • Refractory Hydrothorax

Exclusion Criteria:
  • Non cirrhotic HTP

  • CHILD C ≥12

  • Complete portal vein thrombosis

  • Usual contra-indication for TIPS :

  • Known or suspected Hepatocarcinoma by increase of the alpha-foetoprotein >100 UI/mL associated with the presence of at least one hepatic nodule

  • Cardiac insufficiency defined by a ventricular fraction of ejection < 40% with the echocardiography preliminary to the procedure

  • Pulmonary arterial hypertension (PAP > 40 mmHg)

  • Hepatic polycystosis

  • Intra-hepatic bile ducts dilatation,

  • Spontaneous clinical recurrent hepatic encephalopathy

Contacts and Locations

Locations

Site City State Country Postal Code
1 Chru Bordeaux Bordeaux France 33075
2 Chru Caen Caen France 14033
3 Chru Clermont Ferrand Clermont Ferrand France 63058
4 Chru Dijon Dijon France 21079
5 AP-HM / La Conception Marseille France 13003
6 AP-HM / La Timone Marseille France 13385
7 CHRU NANTES / Hôpital Guillaume et René Laënnec Nantes (st Herblain) France 44800
8 CHRU NANTES / Hôtel-Dieu Nantes France 44093
9 Chru Nice Nice France 06202
10 Chru Poitiers Poitiers France 86021
11 CHRU de TOURS Tours France 37044
12 Ap-Hp (Paul Brousse) Villejuif France 94804

Sponsors and Collaborators

  • University Hospital, Tours

Investigators

  • Principal Investigator: Jean-Marc PERARNAU, Doctor, CHRU TOURS

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
University Hospital, Tours
ClinicalTrials.gov Identifier:
NCT00593528
Other Study ID Numbers:
  • STIC07-JMP/TIPS-PTFE
  • 2007-A00857-46
First Posted:
Jan 15, 2008
Last Update Posted:
Apr 9, 2015
Last Verified:
Apr 1, 2015

Study Results

No Results Posted as of Apr 9, 2015